5.53
-0.1(-1.78%)
Currency In USD
| Previous Close | 5.63 |
| Open | 5.7 |
| Day High | 5.76 |
| Day Low | 5.42 |
| 52-Week High | 29.28 |
| 52-Week Low | 1.62 |
| Volume | 23,373 |
| Average Volume | 729,134 |
| Market Cap | 10.57M |
| PE | -0.29 |
| EPS | -19.25 |
| Moving Average 50 Days | 5.43 |
| Moving Average 200 Days | 5.57 |
| Change | -0.1 |
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
GlobeNewswire Inc.
Sep 29, 2025 11:15 AM GMT
-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half of 2026- -SP16 has demonstrated both anti-inflamma
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 03, 2025 1:15 PM GMT
ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, today announces it will particip
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
GlobeNewswire Inc.
Aug 07, 2025 5:08 PM GMT
- Halneuron® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events amongst the first 35 patients completing the trial sugge
